ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma

Subcutaneous daratumumab plus pomalidomide and dexamethasone reduces risk of progression, death in relapsed/refractory MM
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news